Phase 4 N=189 Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
Bipolar Disorder · Major Depression
Primary: HAM-D 17 Item: Hamilton Depression Rating Scale — 6.6; 4.91; 2.333; 3.75 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Depression, Bipolar · Bipolar Disorder · Mood Disorders
Primary: Number of Participants With Clinical Response [ Time Frame: At 6 Weeks Following Course of tDCS Treatment ] — 34 Participants
N/A N=8 Wake Therapy in the Treatment of Depression
Major Depressive Disorder · Bipolar Disorder
Primary: Structured Interview for the Hamilton Depression Scale With Atypical Depression Supplement(SIGH-ADS) — 16.6 score on a scale
Phase 3 N=505 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -10.7; -15.4; -15.4 units on a scale — p=<0.001
Phase 2 N=341 A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Depressive Episode · Bipolar 1 Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -19.485; -19.324; -16.196 units on a scale — p=0.044
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Phase 4 N=7 Tranylcypromine Treatment of Bipolar Depression
Bipolar Disorder I or II
Primary: 29 Item Hamilton Rating Scale for Depression (HamD29) — 27.0; 5.8 Hamilton Depression score
Phase 2 N=50 Scopolamine in Bipolar Depression
Bipolar Disorder Depression
Primary: Hamilton Depression Rating Scale Score After Last Treatment — 12.0; 13.0 units on a scale — p=0.3
Phase 3 N=488 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Bipolar Depression · Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.1; -12.4 score on a scale — p=<0.0001
Phase 2 N=12 Pramipexole to Target "Anhedonic Depression"
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
Phase 4 N=86 Maintenance Treatment of Bipolar Depression
Bipolar Disorder · Depression
Primary: Mania Rating Scale — 4.54; 5.57 units on a scale
Phase 3 N=525 A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
Bipolar Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -10.6; -13.6; -12.6 units on a scale — p=0.007
N/A N=128 Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention
Major Depressive Disorder · Dysthymic Disorder
Primary: Change From Baseline in Beck Depression Inventory-Second Edition (BDI-II) at the End of Therapy, 3 and 12-month Follow-up — 37.23; 36.94; -17.62; -15.52 units on a scale…
Phase 3 N=57 Lamotrigine for Symptoms of Geriatric Bipolar Depression
Bipolar Disorder · Depression, Bipolar
Primary: Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) — -15.5 units on a scale — p=<.01
N/A N=21 A Pilot Study of the Immediate Effects of DLPFC tDCS on Attention Bias in Depression
Depression
Primary: Beck Depression Inventory (BDI-II) Score — 21.29 score on a scale
N/A N=10 iTBS in Bipolar I Depression
Bipolar Depression · Bipolar I Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score — 16.9 score on a scale
N/A N=26 Transcranial Direct Current Stimulation Therapy for Major Depression
Major Depressive Disorder
Primary: Clinical Response — 22 Participants
Phase 3 N=514 Olanzapine Treatment of Patients With Bipolar I Disorder
Depression, Bipolar
Primary: Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) — 29.36; 28.69; -14.26; -11.71 units on a scale — p=0.018
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
N/A N=21 Depression, Obesity and Inflammatory Markers
Bipolar Disorder · Depression · Obesity
Primary: Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8 — -12.2; -12.0 units on a scale — p=<0.05
Phase 3 N=377 Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Bipolar Depression
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -16.70; -12.12 score on a scale — p=<0.0001
Phase 3 N=62 Bipolar Depression Before and After Lamotrigine Treatment
Bipolar Depression
Primary: Mean Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Baseline for Both Groups, and After 12 Weeks of Lamotrigine Monotherapy for the Bipolar Group — 27.79…
Phase 3 N=356 Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -11.8; -10.4 units on a scale — p=0.176
Phase 3 N=296 Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Bipolar Depression
Primary: Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -15.27; -18.48; 28.8; 28.5 Scores on a…
N/A N=14 Riluzole in the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change in Hamilton Depression Rating Scale — -12.6 units on a scale — p=<.001
N/A N=31 An Open Label Trial of TMS Therapy for Bipolar Depression
Bipolar Depression
Primary: The Percentage of Patients Who Respond or Remit After 30 to 35 Treatments Based Off of the Montgomery-Åsberg Depression Rating Scale (MADRS) — 27; 4; 23; 8 Participants…
Phase 4 N=40 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
Bipolar Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -39.24 Percent change in MADRS from baseline
N/A N=53 Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression
Bipolar Depression
Primary: Long Term Change: Montgomery-Åsberg Depression Rating Scale (MADRS) — -14.03; -9.75 units on a scale — p=<0.049
Phase 3 N=348 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -17.1; -13.5 units on a scale — p=0.005